Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Duncan Richards

Today, we formally welcome Professor Duncan Richards as the new Director to OCTRU, replacing Professor Sarah (Sallie) Lamb who, together with Professor Doug Altman founded the CTU back in 2012. 

Professor Richards, an Oxford-trained clinician, joins OCTRU from his previous roles as Head of Clinical Pharmacology and Experimental Medicine at GSK, and Research Director of GSK’s phase 1 and experimental medicine unit in Cambridge (CUC).

Professor Lamb is moving to a new role at Exeter University, but will continue as Strategic Lead for OCTRU’s Rehabilitation Research group. 

Members of the unit are looking forward to the continued evolution of OCTRU under Professor Richards, building on its reputation as a firmly established CTU conducting numerous clinical trials across all phases and areas of medicine. Professor Richards said: ‘In my short time in Oxford I have been tremendously impressed by the breadth and quality of work undertaken by OCTRU and its partners. I would like to pay tribute Sallie and the team for building a robust but flexible organisation that is ready to take on new challenges and opportunities as the clinical trials portfolio continues to evolve.’

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.